한국임상약학회지 (Korean Journal of Clinical Pharmacy)

  • 제24권2호
  • /
  • Pages.126-134
  • /
  • 2014
  • /
  • 1226-6051(pISSN)
  • /
  • 2508-786X(eISSN)
한국임상약학회 (Korean College Of Clinical Pharmacy)
권호 표지

선택약가제도가 건강보험 약품비 지출에 미치는 영향: 경구용 당뇨병 치료제를 대상으로 한 시나리오 분석

The Effect of Tiered Copayment System on Pharmacy Benefit Expenditure of National Health Insurance in Korea: Scenario Analysis based on the Use of Oral Antidiabetic Medications

  • 투고 : 2013.11.21
  • 심사 : 2014.06.09
  • 발행 : 2014.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: This study was aimed to examine the financial effect of 2-tiered copayment system on annual expenditure of pharmacy benefit in the National Health Insurance (NHI) of Korea, focusing on oral antidiabetic medications. Methods: 284 oral antidiabetic products with 14 different active single ingredients listed in the National Formulary of NHI (August 2009) were assigned to tier 1 or tier 2 according to the selected criteria. 10 different combinations of coinsurance rates were selected to estimate the changes in drug expenditure cost of NHI. Results: The annual drug cost was estimated based on the drug price per unit listed in the National Formulary and the used amount of products in 2009 from the IMS Health data of Korea. In the combinations of coinsurance rate of 20% for tier 1 and 40% for tier 2, the total annual drug cost was estimated to be reduced by 1.3% in the case of no change of generic and original drug consumptions, and to be reduced by 4.3% in the case of 10% increased generic drug consumptions. Conclusion: The tiered copayment system with optimal coinsurance rates appears to be a potential strategy to reduce the financial burden of NHI in Korea by promoting the use of generic products.

키워드

참고문헌

  1. Health Insurance Review & Assessment Service. Statistics on Treatment Amount. 2005-2011. Available at http://www. hira.or.kr/dummy.do?pgmid=HIRAA020045030000. Accessed on March 2, 2013.
  2. Press Release of Ministry of Health & Welfare. The Measures to reform the drug-pricing policy and develop the pharmaceutical industry. Available at http://www.mw.go.kr/ front_new/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ ID=0403&page=96&CONT_SEQ=258276. Accessed on March 2, 2013.
  3. Shin YS. Social Insurance: For a Restructured Basic Oldage Pension and a Sustainable Health Insurance. Health and Welfare Policy Forum 2010; 8: 48-54.
  4. Navarro RP. Managed Care Pharmacy Practice Second Edition. Massachussetts, U.S.: Jones and Bartlett Publishers 2009: 36-40.
  5. Medco. 2007 Drug trend report. Available at http:// citeseerx.ist.psu.edu/viewdoc/download;jsessionid=A23DF 853DE8761F475DC1549FFCA7E1D?doi=10.1.1.175.8475& rep=rep1&type=pdf. Accessed on May 1, 2014.
  6. Kaiser Family Foundation, Health Research & Educational Trust. Employer Health Benefits. 2012 Annual Survey. Available at http://kaiserfamilyfoundation.files.wordpress. com/2013/03/8345-employer-health-benefits-annual-surveyfull- report-0912.pdf. Accessed on August 20, 2013.
  7. Rector TS, Finch MD, Danzon PM, et al. Effect of Tiered Prescription Copayments on the Use of Preferred Brand Medications. Medical Care. 2003; 41(3): 398-406.
  8. Joyce GF, Escarce JJ, Solomon MD, et al. Employer Drug Benefit Plans and Spending on Prescription Drugs. Journal of the American Medical Association. 2002; 288(14): 1733-9. https://doi.org/10.1001/jama.288.14.1733
  9. The Korea Institute for Health and Social Affairs. Policy Measures to Differentiate Drug Insurance Benefits by the Therapeutic Characteristics of Drugs 2004.
  10. Health Insurance Policy Institute. Development of a Road Map for Systematical Management of Pharmacy Benefit Expenditure of National Health Insurance 2012.
  11. Korea Centers for Disease Control & Prevention. The Fourth Korea National Health & Nutrition Examination Survey, The Second Year (2008). 2009.
  12. Korean Diabetes Association / Korean Diabetes Research Foundation / International Conference on Diabetes and Metabolism 2013. Diabetes Fact Sheet in Korea 2013. Available at http://www.diabetes.or.kr/temp/diabetes_factsheet_ 2013111.pdf. Accessed on Mar 1, 2014.
  13. Press Release of Health Insurance Review & Assessment Service. Average Annual Out-of-pocket Pharmacy Expenditure per Outpatient is 80,000 KRW. Available at http://hira.or.kr/ dummy.do?pgmid=HIRAA020041000000&cmsurl=/cms/ notice/02/news,1,list,45.html. Accessed on June 19, 2013.
  14. Press Release of Ministry of Health & Welfare. National Health Insurance, Coverage Expansion in the Field of Cancer and Dentistry. Available at http://www.mohw.go.kr/ front_new/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ ID=0403&page=1&CONT_SEQ=215388&SEARCHKEY= TITLE&SEARCHVALUE=%BA%B8%C0%E5%BC%BA. Accessed on June 19, 2013.
  15. National Health Insurance Act Enforcement Ordinance (Presidential Decree No. 24588, Effective on 2013.7.1) Article 19, Attachment 2. Available at http://www.nhis.or. kr/portal/site/main/MENU_WBDDD01. Accessed on July 1, 2013.
  16. National Health Insurance Act Enforcement Regulation (Ministry of Health & Welfare Decree No. 200, Effective on 2016.6.28) Article 13, Attachment 4. Available at http:// www.nhis.or.kr/portal/site/main/MENU_WBDDD01. Accessed on June 28, 2013.
  17. National Drug Formulary as of 2010.8.1 (Reflection of Ministry of Health & Welfare notification No. 2010-55). Available at http://www.hira.or.kr/dummy.do?pgmid= HIRAA030014050000&cmsurl=/cms/information/02/01/06/ 1200786_25372.html&subject=2010.8.1+%ED%98%84%E C%9E%AC+%EC%95%BD%EC%A0%9C%EA%B8%89 %EC%97%AC%EB%AA%A9%EB%A1%9D%282010.7.2 7+%EA%B3%A0%EC%8B%9C+%EB%B0%98%EC%98 %81%29. Accessed on August 1, 2013.
  18. Press Release of Ministry of Food and Drug Safety. Stop Use of Rosiglitazone, and Limited Use for Patients Who Have No Alternatives. Available at http://www.mfds.go.kr/ index.do?mid=675&seq=13453&cmd=v. Accessed on November 2, 2013.
  19. IMS Health Korea. MAT-12/2009 ST-CNT.UNIT. 2009.
  20. Amendment of 'Calculation Standard of Patient Out-of Pocket Expense' (Ministry of Health & Welfare No. 2011- 86). Available at http://www.mw.go.kr/front_new/jb/sjb0402 vw.jsp?PAR_MENU_ID=03&MENU_ID=030402&page=1 &CONT_SEQ=258099&SEARCHKEY=TITLE&SEARCH VALUE. Accessed on December 1st, 2011.
  21. Regulation on Drug Safety (Ordinance of the Prime Minister No. 1022, Effective on 2013.3.23) Item 3 of Clause 1 of Article 4. Available at http://www.law.go.kr/lsInfoP.do?lsiSeq =137939&efYd=20130323#0000. Accessed on August 20, 2013.
  22. Lee EK, Kim DS. Analysis of Perception on the Bioequivalence-assured Generic Drugs. Kor J Clin Pharm 2006; 16(2): 139-46.
  23. Medicare.gov. The official U.S. Government Site for Medicare. Available at http://www.medicare.gov/part-d/costs/ coverage-gap/part-d-coverage-gap.html. Accessed on Nov 2013.
  24. Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care. 2005; 11(5): S170-6.
  25. Huskamp HA, Deverka PA, Epstein AM, et al. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003; 349(23): 2224-32. https://doi.org/10.1056/NEJMsa030954
  26. Lee IH, Bloor K, Hewitt C, et al. The effects of new pricing and copayment schemes for pharmaceuticals in South Korea. Health Policy. 2012; 104(1): 40-9. https://doi.org/10.1016/j.healthpol.2011.09.003